The purpose of the study was to compare the results of panretinal photocoagulation (PRP) using the pattern scan laser (PASCAL) in a single setting versus multiple sessions of standard YAG laser in patients with proliferative diabetic retinopathy. Charts of 35 eyes that were treated with the PASCAL and an equal number of eyes that were treated with conventional laser were retrospectively reviewed. The whole PRP treatment was performed in one session in the PASCAL group, whereas all the patients in the conventional-laser group completed the entire PRP treatment in two or three sessions. Persistence and/or recurrence of neovascularization, complications encountered, total number of laser spots, and mean power used were compared. Patients treated with the PASCAL received significantly higher number of laser spots than those treated with conventional laser (2885 vs. 1642, p < 0.001). The PASCAL and conventional-laser systems required an average power of 650 mW and 330 mW, respectively (p < 0.001). Patients treated with the PASCAL showed similar rates of treatment failure within 12 months of follow-up compared with patients treated with conventional laser (14% vs. 11%, p > 0.05). In the PASCAL group, vitreous hemorrhage, neovascular glaucoma, retinal hemorrhage, and choroidal detachment were reported in two, two, one, and two patients, respectively, whereas only one each vitreous hemorrhage and neovascular glaucoma were encountered in the conventional-laser group. Our study reports that single-session PRP with the PASCAL has similar efficacy compared with conventional laser, and has a favorable side-effect profile.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.kjms.2015.12.002 | DOI Listing |
Retin Cases Brief Rep
December 2024
Casey Eye Institute, Oregon Health & Science University, Portland, OR.
Purpose: To describe two cases of pediatric patients with Coats disease who developed nerve fiber layer (NFL) schisis.
Methods: Observational case series.
Results: Two male pediatric patients, ages 2 and 14, who were being treated for Coats disease were found to have NFL schisis on optical coherence tomography.
Clin Ophthalmol
December 2024
Department of Ophthalmology and Visual Sciences, W. K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI, USA.
Doc Ophthalmol
December 2024
Save Sight Institute Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Purpose: Multiple mitochondrial syndromes, such as Kearns-Sayre, involve the concurrence of diabetes mellitus and inherited pigmentary retinopathy. It is rare, however, for proliferative disease to develop in these patients as existing inner retinal dysfunction is thought to be protective.
Methods: To our knowledge this is the first description of proliferative diabetic retinopathy (PDR) in Kearns-Sayre syndrome.
Int J Retina Vitreous
December 2024
Retina Service, Farabi Eye Hospital, Tehran University of Medical Sciences, South Kargar Street, Qazvin Square, Tehran, Iran.
Background: This retrospective study aimed to compare optic disc vasculature changes in 1 and 3 months after treatment with either panretinal photocoagulation (PRP) or Intravitreal bevacizumab (IVB) in patients with diabetic retinopathy.
Methods: A total of 50 eyes of 29 diabetic patients without severe complications were included in this comparative case series. Of these, twenty-eight eyes (15 patients) were assigned to the PRP group, while twenty-two eyes (14 patients) were treated with the biosimilar (IVB) (Stivant CinnaGen Co.
Case Rep Ophthalmol Med
December 2024
Queensland Eye Institute, Brisbane, Queensland, Australia.
To describe a case of regression of proliferative diabetic retinopathy (PDR) following treatment with semaglutide. Case report. The case describes a 47-year-old woman with Type 2 diabetes, obesity, hypertension, and dyslipidaemia who had difficulty controlling her blood sugar levels despite oral hypoglycaemic medications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!